# Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis

> **NCT05168384** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abu Dhabi Stem Cells Center** · enrollment: 15 (actual)

## Conditions studied

- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive

## Interventions

- **COMBINATION_PRODUCT:** Extracorporeal Photopheresis
- **COMBINATION_PRODUCT:** MS standard of care

## Key facts

- **NCT ID:** NCT05168384
- **Lead sponsor:** Abu Dhabi Stem Cells Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-26
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-04-27
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05168384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05168384, "Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT05168384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*